Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19129796 | 0.93 | TDP1 (0.43) | TDP1NR1H4GPBAR1PRKCD | |
| SCHEMBL19125269 | 0.92 | TDP1 (0.50) | TDP1NR1H4GPBAR1PRKCD | |
| SCHEMBL19129813 | 0.88 | GPBAR1 (0.54) | TDP1GPBAR1PRKCD | |
| SCHEMBL19129795 | 0.87 | TDP1 (0.43) | TDP1NR1H4GPBAR1PRKCD | |
| SCHEMBL19129752 | 0.87 | NR1H4 (0.46) | NR1H4GPBAR1PRKCD | |
| SCHEMBL19124473 | 0.85 | NR1H4 (0.46) | TDP1NR1H4GPBAR1 | |
| SCHEMBL17380751 | 0.81 | GPBAR1 (0.54) | TDP1GPBAR1PRKCD | |
| SCHEMBL17380755 | 0.81 | GPBAR1 (0.54) | TDP1GPBAR1PRKCD | |
| SCHEMBL12698329 | 0.80 | NR1H4 (0.46) | NR1H4GPBAR1PRKCD | |
| SCHEMBL19124752 | 0.80 | GPBAR1 (0.51) | TDP1NR1H4GPBAR1PRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920090-B2 | Betulinic acid derivatives with HIV maturation inhibitory activity | VIIV Healthcare UK (No.5) Limited (GB) | 2018-03-20 | — | — | US | disclosed |
| US-20170204133-A1 | BETULINIC ACID DERIVATIVES WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204133-A1 | BETULINIC ACID DERIVATIVES WITH HIV MATURATION INHIBITORY ACTIVITY | BET1, PGGT1B, TMPO | TDP1 3124/4885NR1H4 2291/4885GPBAR1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.